Effect of L-carnitine supplementation on inflammatory marker of coronary artery disease


  • Abhishek Singhai Department of Medicine, Sri Aurobindo Medical College & PGI, Indore, Madhya Pradesh, India
  • Vishal Yadav Department of Medicine, Sri Aurobindo Medical College & PGI, Indore, Madhya Pradesh, India
  • Rajesh Kumar Jha Department of Medicine, Sri Aurobindo Medical College & PGI, Indore, Madhya Pradesh, India




CRP, Coronary artery disease, Inflammation, L-carnitine


Background: L-carnitine (LC) might have the potential to control inflammation by reduction of major inflammatory cytokines, including CRP.  Therefore, this study was planned to investigate the effect of LC supplementation on CRP levels in CAD patients.

Methods: 50 subjects comprised placebo group who received standard line of treatment for coronary artery disease while other 50 subjects comprised LC group who received 1000 mg of LC daily apart from standard treatment for 12 weeks. CRP levels were measured at baseline and again after 12 weeks of treatment in all subjects.

Results: The participants in the LC group had significantly lower levels of CRP after 12 weeks of supplementation with LC, than at baseline (p<0.01).

Conclusions: We suggest that LC supplementation, due to its antioxidant effects, have potential utility to reduce inflammation in CAD.


Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New England J Medicine. 2004;350:1387-97.

Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169-77.

Clyne B, Olshaker JS. The C-reactive protein. J Emergency Medicine. 1999;17:1019-25.

Ananthanarayan R, Paniker C. Ananthanarayan and Paniker's Textbook of Microbiology (7th ed.).: Orient Longman. p. 218. ISBN 9788125028086.

Tillett WS, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Experimental Medicine. 1930;52:561-71.

Kennelly PJ, Murray RF, Rodwell VW, Botham KM. Harper's illustrated biochemistry 2009. McGraw-Hill Medical. ISBN 0-07-162591-7.

Lee BJ, Lin JS, Lin YC, Lin PT. Anti-inflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition. 2015;31:475-9.

Gülçin L. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006;78(8):803-11.

Singh RB, Aslam M. L-carnitine administration in coronary artery disease and cardiomyopathy. J Assoc Physicians India. 1998;46(9):801-5.






Original Research Articles